A new study shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal — such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.
A new study shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal — such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.